| Catalog No. | Size | Price (USD) |
| 111263-R0025-20 | 20 µL | $103.53 |
| 111263-R0025-100 | 100 µL | $296.07 |
General Information
| Product name | Phospho-ATR (Ser428) Antibody, Rabbit MAb |
| Validated applications | WB (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Phospho-ATR (Ser428) |
| Immunogen | A synthetic peptide corresponding to residues around Ser428 of Human ATR |
| Preparation | This antibody was obtained from a rabbit immunized with a synthetic peptide corresponding to residues around Ser428 of Human ATR. |
| Source | Monoclonal Rabbit IgG Clone #0025 |
| Purification | Protein A |
| Formulation | 10 mM sodium HEPES, 150 mM NaCl, 100 μg/mL BSA, 50% glycerol, pH 7.5 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-FCTCS Antibody; Anti-FRP1 Antibody; Anti-MEC1 Antibody; Anti-SCKL Antibody; Anti-SCKL1 Antibody
Image / Experimental Information
| Image 1 Description | Western blot analysis of extracts from Hela, untreated(line A) or treated with hydroxyurea(4mM, 24h; +)(line B), using Phospho-ATR (Ser428) rabbit monoclonal Antibody (Cat: 111263-R0025 ) at 1:1000 dilution. |
| Image 1 Alt Text | Human ATR Western blot (WB) 48266 |
| Image 1 URL | Source image |
| Image 2 Description | Western blot analysis of extracts from Hela, untreated(line A) or treated with hydroxyurea(4mM, 24h; +)(line B), using Phospho-ATR (Ser428) rabbit monoclonal Antibody (Cat: 111263-R0025 ) at 1:1000 dilution. |
| Image 2 Alt Text | Human ATR Western blot (WB) 48267 |
| Image 2 URL | Source image |
Background Information
| Description | ATR is a serine/threonine protein kinase and ATR kinase inhibitors potentiate chemotherapy and radiation. The ATR kinase inhibitor VX-970 (NSC 780162) is in clinical development in combination with primary cytotoxic agents and as a monotherapy for tumors harboring specific mutations. Nucleotide excision repair (NER) is the sole mechanism of UV-induced DNA lesion repair in mammals. A single round of NER requires multiple components including seven core NER factors, xeroderma pigmentosum A-G (XPA-XPG), and many auxiliary effector proteins including ATR serine/threonine kinase. The ataxia telangiectasia mutated serine/threonine kinase (ATM)/checkpoint kinase 2 (CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase (ATR)/CHEK1 (best known as CHK1) cascades are the 2 major signaling pathways driving the DNA damage response (DDR), a network of processes crucial for the preservation of genomic stability that act as a barrier against tumorigenesis and tumor progression. |
| Research Areas |
|
